United Therapeutics Remodulin
Executive Summary
United Therapeutics will resubmit NDA for Remodulin Aug. 10 if the product receives a positive review from FDA's Cardiovascular & Renal Drugs Advisory Committee Aug. 9. The company withdrew the application for Remodulin (formerly Uniprost) for pulmonary arterial hypertension shortly before the product's July 16 user fee deadline. "Because the Aug. 9 advisory committee meeting fell outside the [Prescription Drug Use Fee Act] time period, the company was required to withdraw its NDA and will resubmit it upon a favorable advisory committee recommendation by the following day, Aug. 10," United Therapeutics said
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth